Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;56(3):223-234.
doi: 10.1055/a-2236-8625. Epub 2024 Jan 2.

The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice

Laura Wörmeyer  1   2 , Oliver Nortmann  1   2 , Anna Hamacher  2 , Celina Uhlemeyer  3   4 , Bengt Belgardt  3   4 , Daniel Eberhard  2 , Ertan Mayatepek  1 , Thomas Meissner  1 , Eckhard Lammert  2   3   4 , Alena Welters  1   3
Affiliations

The N-Methyl-D-Aspartate Receptor Antagonist Dextromethorphan Improves Glucose Homeostasis and Preserves Pancreatic Islets in NOD Mice

Laura Wörmeyer et al. Horm Metab Res. 2024 Mar.

Abstract

For treatment of type 1 diabetes mellitus, a combination of immune-based interventions and medication to promote beta-cell survival and proliferation has been proposed. Dextromethorphan (DXM) is an N-methyl-D-aspartate receptor antagonist with a good safety profile, and to date, preclinical and clinical evidence for blood glucose-lowering and islet-cell-protective effects of DXM have only been provided for animals and individuals with type 2 diabetes mellitus. Here, we assessed the potential anti-diabetic effects of DXM in the non-obese diabetic mouse model of type 1 diabetes. More specifically, we showed that DXM treatment led to five-fold higher numbers of pancreatic islets and more than two-fold larger alpha- and beta-cell areas compared to untreated mice. Further, DXM treatment improved glucose homeostasis and reduced diabetes incidence by 50%. Our data highlight DXM as a novel candidate for adjunct treatment of preclinical or recent-onset type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

A.W., T.M., E.M. and E.L. declare the following competing financial interests: these authors are inventors of the US patent 10,464,904 entitled “Dextrorphan-derivatives with suppressed central nervous activity”; and T.M. and E.L. are inventors of the US patent 9,370,511 entitled “Morphinan-derivatives for treating diabetes and related disorders.”

Figures

Fig. 1
Fig. 1
In the type 1 diabetes mouse model NOD, treatment with dextromethorphan delays diabetes onset and improves glucose tolerance. a : Schematic timeline of the experimental setup: 4 week-old female NOD mice continuously received either normal drinking water (control group) or 3 g/l dextromethorphan via drinking water (DXM group); mice were euthanized at the age of 10 weeks (prediabetic mice: green), at diabetes onset, defined as a random blood glucose concentration ≥250 mg/dl on two consecutive days (diabetic mice: red), or following a maximum of 26 weeks of DXM treatment at the age of 30 weeks (non-diabetic mice: blue). b : Kaplan–Meier curve indicating the incidence of diabetes in DXM-treated NOD mice compared to control NOD mice (n=12 mice per treatment group). c : Blood glucose concentrations of 10–11 week-old female NOD mice during an intraperitoneal glucose tolerance test (1.5 mg g -1 body weight) either treated or untreated with DXM via the drinking water starting at the age of 4 weeks (n=11 control and n=12 DXM-treated mice). d : Random blood glucose concentrations of either DXM-treated or control NOD mice at diabetes onset (n=8 control and n=4 DXM-treated mice). Statistical significance determined by Mantel–Cox log-rank test, p=0.0915 ( b ), multiple Student’s t -test ( c ), and unpaired Student’s t -test ( d ). Data in ( c ) and ( d ) are presented as mean ± SD ( c ) and mean ± SEM ( d ).
Fig. 2
Fig. 2
DXM treatment increases islet numbers, as well as beta- and alpha-cell areas in NOD mice. a : Representative fluorescence microscopy images of pancreatic sections from 30 week-old non-diabetic NOD mice, either untreated (control) or continuously treated with DXM over 26 weeks (DXM); blue: DAPI; red: insulin; scale bar: 1000 μm (≥16 cross-sections from n ≥4 mice per treatment group). ( b ) Islet numbers, ( c ) beta- and ( d ) alpha-cell areas within pancreatic sections of 30 week-old non-diabetic NOD mice treated as described in ( a ) (≥16 sections from n ≥4 mice per treatment group). Statistical significance determined by unpaired Student’s t -test. Data are shown as mean ± SEM.
Fig. 3
Fig. 3
DXM treatment numerically reduces the number of apoptotic islet-cells but has no effect on islet-cell proliferation in NOD mice. a : Islet numbers per total pancreatic nuclei area in 10 week-old prediabetic, 12–30 week-old diabetic and 30 week-old non-diabetic NOD mice, either untreated (control) or continuously treated with DXM since 4 weeks old (DXM), dashed lines indicate separate cohorts (n ≥4 mice per treatment group). b : Representative LSM images of pancreatic islets from 10 week-old prediabetic NOD mice treated as described in ( a ); blue: DAPI; red: insulin; grey: cleaved caspase-3 (≥47 islets per mouse from n=6 mice per treatment group). c : Cleaved caspase-3-positive area per islet area (≥47 islets per mouse from n=6 mice per treatment group). d : Representative LSM images of pancreatic islets from mice treated as described in ( b ); blue: DAPI; red: insulin; green: Ki67; arrow heads: Ki67-positive cell nuclei within pancreatic islet (≥38 islets per mouse from n=6 mice per treatment group). e : Number of Ki67-positive cells per islet area (≥38 islets per mouse from n=6 mice per treatment group). Scale bars: 50 μm. Statistical significance determined by unpaired Student’s t -test comparing treatment groups. Data are shown as mean ± SEM.
Fig. 4
Fig. 4
DXM treatment reduces the number of infiltrating T-cells, particularly CD8-positive T-lymphocytes. a : Representative fluorescence microscopy images of pancreatic islets from 10 week-old prediabetic NOD mice either untreated (control) or DXM-treated for 6 weeks (DXM); blue: DAPI; red: insulin; green: CD45; scale bar: 100 μm (≥60 islets per mouse from n=6 mice per treatment group). b : Insulitis score and ( c ) CD45-positive area per islet area of the same mice (≥60 islets per mouse from n=6 mice per treatment group). d : Representative LSM images of pancreatic islets from mice treated as described in ( a ); blue: DAPI; green: insulin; red: CD8; grey: CD4; scale bar: 50 μm (≥ 40 islets per mouse from n=6 mice per treatment group). e : CD4- and ( f ) CD8-positive area per total pancreatic nuclei area of the same mice (≥40 islets per mouse from n=6 mice per treatment group). Statistical significance determined by unpaired Student’s t -test comparing treatment groups. Data in ( c ), ( e ) and ( f ) are shown as mean±SEM.
Fig. 5
Fig. 5
DXO treatment decreases the expression of chemokines in pancreatic islets. a , b : Relative mRNA expression of Cx3cl1 , Cxcl1 , Cxcl2 , Cxcl16 , and Ccl2 normalized to the expression of Rplp0 of either untreated islets compared to islets treated for 24 hours with 1 μM DXO ( a ) or of islets treated for 24 hours with cytokines (IFNγ, IL-1β, TNFα) in the presence or absence of 1 μM DXO ( b ) (n=5 independent experiments). c : Concentration of CCL2 in supernatants of islets treated as described in ( b ) (n=5 per condition). Statistical significance determined by paired ( a , b ) or unpaired ( c ) Student’s t -test comparing treatments with or without DXO.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Boscari F, Avogaro A. Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Rev Endocr Metab Disord. 2021;22:217–240. - PMC - PubMed
    1. Beck R W, Bergenstal R M, Laffel L M et al.Advances in technology for management of type 1 diabetes. Lancet. 2019;394:1265–1273. - PubMed
    1. Boughton C K, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021;64:1007–1015. - PMC - PubMed
    1. Kramer C K, Retnakaran R, Zinman B. Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. Cell Metab. 2021;33:740–747. - PubMed
    1. Foster N C, Beck R W, Miller K M et al.State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21:66–72. - PMC - PubMed